AL002 TREM2 Agonist for Alzheimer's Disease
Overview
AL002 is a novel humanized IgG1 monoclonal antibody developed by Alector Inc. that functions as a potent agonist of TREM2 (Triggering Receptor Expressed on Myeloid Cells 2), a critical receptor expressed primarily on microglia in the central nervous system. This therapeutic candidate was designed to target the innate immune dysfunction that characterizes Alzheimer's disease (AD) by enhancing microglial-mediated clearance of amyloid-beta plaques and promoting neuroprotective microglial activation states.
The development of AL002 represents a paradigm shift in AD therapeutic strategies, moving beyond the traditional amyloid-targeting approaches to address the neuroimmune axis of neurodegeneration. TREM2 has emerged as one of the most significant genetic risk factors for AD following the discovery that common variants, particularly the R47H substitution, increase AD risk by approximately 3-fold—a effect size comparable to the APOE ε4 allele.
AL002 is also a TREM2-activating monoclonal antibody developed by [Alector Inc.](https://www.alector.com/) as a potential disease-modifying treatment for Alzheimer's disease. TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a receptor on microglia that plays a critical role in the brain's immune response to amyloid plaques. AL002 represents one of several TREM2-targeting approaches in clinical development, representing a novel mechanism in AD therapeutics.
TREM2 Biology and AD Pathogenesis
TREM2 Structure and Function
TREM2 is a transmembrane receptor belonging to the TREM family of pattern recognition receptors. It is expressed predominantly on microglia in the brain and on peripheral myeloid cells including monocytes and macrophages. The receptor recognizes a broad range of ligands including lipoproteins, apolipoproteins, amyloid-beta fibrils, and phosphatidylserine on apoptotic cells.
Upon ligand binding, TREM2 signals through the adaptor protein DAP12 (TYROBP), which contains an immunoreceptor tyrosine-based activation motif (ITAM). This signaling cascade activates Syk kinase and downstream pathways including PI3K/AKT, MAPK, and NF-κB, leading to microglial proliferation, survival, phagocytosis, and inflammatory cytokine production.
TREM2 Genetic Variants and AD Risk
The discovery of rare coding variants in TREM2 that cause a highly penetrant form of frontotemporal dementia (FTD) with pyramidal signs established TREM2 as a critical regulator of microglial function. Subsequent genome-wide association studies identified the common TREM2 R47H variant (rs75932628) as a significant risk factor for late-onset Alzheimer's disease, with an odds ratio of approximately 2.5-3.0 for heterozygous carriers.
This variant impairs TREM2 signaling by reducing ligand binding affinity and disrupting downstream signal transduction. Carriers of R47H demonstrate:
- Reduced microglial phagocytic capacity for amyloid-beta
- Impaired microglial survival under stress conditions
- Altered microglial transcriptional responses to amyloid pathology
- Increased accumulation of amyloid plaques in the brain
Microglial States in AD
Advances in single-cell RNA sequencing have revealed remarkable heterogeneity in microglial populations in the AD brain. TREM2 plays a central role in the transition between discrete microglial states:
Homeostatic Microglia: In the normal brain, TREM2 expression is relatively low. These microglia maintain surveillance functions and support neuronal health through trophic factor release.
Disease-Associated Microglia (DAM): In response to AD pathology, microglia upregulate TREM2 and adopt a protective phenotype characterized by increased phagocytic activity, lipid metabolism, and neuroprotective gene expression. This transition requires TREM2 signaling.
Neuroinflammatory Microglia: In advanced AD, microglia may adopt a pro-inflammatory phenotype that contributes to synaptic loss and neuronal damage. The balance between protective DAM and destructive inflammatory states is influenced by TREM2 activity.
Mechanism of Action
Microglial Activation Pathway
Mermaid diagram (expand to render)
AL002 is designed to activate TREM2 signaling in microglia, which may:
- Enhance phagocytosis: AL002 stimulates microglial clearance of amyloid-beta plaques through enhanced TREM2 signaling, as demonstrated in preclinical models showing increased plaque clearance in the presence of TREM2 agonism
- Promote microglial survival: TREM2 activation provides pro-survival signals through the PI3K/AKT pathway, helping microglia persist in the hostile AD microenvironment
- Reduce neuroinflammation: Properly activated microglia may adopt a more protective phenotype, reducing harmful chronic inflammation while maintaining surveillance functions
- Support DAM transition: TREM2 agonism promotes the transition of microglia to a protective "disease-associated microglia" (DAM) state, characterized by enhanced phagocytic capacity and trophic support
Genetic Validation
The therapeutic rationale for TREM2 activation is strongly supported by genetics:
- R47H variant: The TREM2 R47H variant significantly increases AD risk by approximately 3-fold (OR ~3.5)
- Other risk variants: Additional TREM2 variants (R62H, D87N) also associate with increased AD risk
- Loss-of-function: These risk variants appear to cause partial loss of TREM2 function, suggesting that enhancing TREM2 activity could be therapeutic
- Dosage effect: TREM2 expression levels correlate with cognitive outcomes, supporting the agonism approach
AL002 is a novel TREM2-activating monoclonal antibody developed by Alector Inc. as a potential disease-modifying treatment for Alzheimer's disease (AD). TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a critical receptor on microglia—the immune cells of the brain—that plays an essential role in the brain's immune response to amyloid plaques. By activating TREM2 signaling, AL002 aims to enhance microglial phagocytosis of amyloid-beta, reduce neuroinflammation, and potentially slow or halt disease progression in early AD[@schlepckow2024][@wang2023].
The development of AL002 represents a fundamentally different approach to Alzheimer's disease treatment compared to amyloid-targeting antibodies like lecanemab and donanemab. Rather than removing amyloid plaques directly, AL002 aims to enhance the brain's own immune clearance mechanisms by activating microglia, the cells responsible for clearing pathological aggregates.
TREM2 Biology: The Therapeutic Target
TREM2 Structure and Function
TREM2 is a transmembrane receptor belonging to the immunoglobulin superfamily, expressed primarily on microglia in the central nervous system. It functions as an essential regulator of microglial activity, survival, and phenotypic transformation.
Key Structural Features:
- Type I transmembrane protein with an extracellular immunoglobulin-like domain
- Ligands include amyloid-beta plaques, apolipoproteins (ApoE, ApoJ), and lipid components
- Signaling occurs through association with the adaptor protein DAP12 (TYROBP)
- DAP12 contains an immunoreceptor tyrosine-based activation motif (ITAM)
Core Signaling Pathways:
- Activation of Syk kinase through DAP12 ITAM phosphorylation
- Downstream activation of PI3K/Akt, MAPK, and NF-κB pathways
- Enhancement of microglial survival, proliferation, and phagocytic activity
TREM2 in Alzheimer's Disease Pathogenesis
The role of TREM2 in AD has been clarified through genetic studies, with the TREM2 R47H variant providing crucial insights:
Genetic Evidence:
- The R47H variant increases AD risk approximately 3-4 fold (similar to APOE4)
- This variant impairs ligand binding (amyloid, ApoE)
- Reduced TREM2 signaling compromises microglial function
- Carriers show increased amyloid deposition and faster progression
TREM2 in Normal Microglia Function:
- Promotes microglial survival and proliferation
- Enhances phagocytic clearance of amyloid plaques
- Supports transition to protective "disease-associated microglia" (DAM) or "neurodegenerative microglia" (MGnD) phenotype
- Modulates neuroinflammation toward a protective state
In AD, TREM2 dysfunction leads to:
- Impaired amyloid clearance
- Accumulation of toxic oligomers and plaques
- Dysregulated neuroinflammation
- Accelerated disease progression
Mechanism of Action
AL002 is designed to activate TREM2 signaling in microglia, bypassing the functional deficits caused by risk variants like R47H. The therapeutic mechanism involves multiple beneficial effects:
Enhanced Amyloid Clearance
Phagocytosis Enhancement
- TREM2 activation dramatically increases microglial phagocytosis of amyloid-beta
- Activated microglia show improved plaque clearance
- May reduce the burden of toxic soluble oligomers
Plaque-Associated Microglia
- TREM2 is required for proper recruitment of microglia to amyloid plaques
- Activated microglia form a protective barrier around plaques
- May limit plaque-associated neuritic damage
Phase 1 Study (AL002-101)
The first-in-human Phase 1 study (NCT03635047) evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL002 in 64 healthy volunteers and patients with early AD.
Study Design:
- Randomized, placebo-controlled, double-blind single ascending dose (SAD) study
- Dose escalation from 0.003 mg/kg to 60 mg/kg
- Single intravenous infusion
- 12-week follow-up period
Key Findings:
Microglial Survival and Function
Cell Survival Signaling
- TREM2 activation promotes microglial survival via PI3K/Akt pathway
- Prevents apoptosis of plaque-associated microglia
- Supports microglial population maintenance
Metabolic Support
- TREM2 activation enhances microglial metabolic function
- Supports the high energy demands of active phagocytosis
- Improves mitochondrial function
Anti-inflammatory Effects
Neuroinflammation Modulation
- TREM2 activation can shift microglia toward an anti-inflammatory phenotype
- Reduces production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
- May protect against chronic neuroinflammation-driven neurodegeneration
Disease-Associated Microglia (DAM) Transition
- TREM2 is required for the transition to protective DAM state
- DAM cells show enhanced phagocytosis and tissue repair functions
- AL002 aims to promote this beneficial phenotypic transition
A unique advantage of the TREM2 agonism approach:
- Amyloid-targeting antibodies carry significant ARIA risk (brain edema, microhemorrhages)
- TREM2 agonism enhances endogenous clearance rather than causing antibody-mediated plaque disruption
- May result in lower ARIA rates compared to direct amyloid removal
Clinical Development Program
Phase 1 Study (AL002-101)
The first-in-human Phase 1 study (NCT03635047) evaluated the safety, tolerability, and pharmacokinetics of AL002 in healthy volunteers and patients with early AD. Key findings included:
- Safety profile: AL002 was generally well-tolerated at all doses tested
- Target engagement: Evidence of TREM2 engagement in the CNS through CSF biomarker changes
- Pharmacokinetics: Suitable exposure achieved with intravenous administration
- Dose selection: Doses selected for Phase 2 based on safety and target engagement data
Phase 2 Study (INVOKE-1)
The INVOKE-1 trial (NCT04592874) is a Phase 2, randomized, double-blind, placebo-controlled study evaluating AL002 in patients with early Alzheimer's disease.
| Trial | Phase | Status | NCT Number | Key Details |
|-------|-------|--------|------------|--------------|
| AL002-101 | Phase 1 | Completed | NCT03635047 | Safe, tolerable, target engagement demonstrated |
| INVOKE-1 | Phase 2 | Completed | NCT04592874 | Primary endpoint not met; target engagement confirmed |
Study Design:
- Single ascending dose in healthy volunteers
- Multiple ascending dose in early AD patients (MCI due to AD, mild AD dementia)
- Randomized, placebo-controlled, double-blind
Key Findings:
- AL002 was generally well-tolerated at all dose levels
- Dose-proportional pharmacokinetics
- Evidence of target engagement (CSF biomarker changes)
- No severe ARIA events observed at therapeutic doses
Phase 2 Study (INVOKE-1)
AL002 is currently being evaluated in the INVOKE-1 Phase 2 trial, a randomized, double-blind, placebo-controlled study in patients with early Alzheimer's disease.
| Study | Phase | Status | NCT Number |
|-------|-------|--------|------------|
| AL002-101 | Phase 1 | Completed | NCT03635047 |
| INVOKE-1 | Phase 2 | Recruiting | NCT04592874 |
INVOKE-1 Trial Design:
Patient Population:
- Early AD (MCI due to AD or mild AD dementia)
- Confirmed amyloid positivity (PET or CSF)
- MMSE score 20-30
- Age 55-85 years
Primary Endpoint: Change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) at week 96
Results:
- Primary endpoint not met (all P > 0.05 vs placebo)
- Least squares mean differences vs placebo ranged from -0.31 to 0.13
- Target engagement confirmed: sustained reductions in soluble TREM2
- Pharmacodynamic response: increased CSF osteopontin levels
Safety Profile:
- Most frequent treatment-emergent adverse events: ARIA-like MRI changes
- Manageable safety profile consistent with Phase 1 data
Biomarkers and Target Engagement
The AL002 clinical program has established robust biomarker endpoints that demonstrate target engagement and pharmacodynamic activity:
Soluble TREM2 (sTREM2)
sTREM2 is generated by proteolytic shedding of the TREM2 extracellular domain. Levels of sTREM2 in CSF reflect TREM2 expression and activation state on microglia. AL002 treatment leads to dose-dependent reduction in CSF sTREM2, consistent with:
- Antibody-mediated internalization of cell surface TREM2
- Reduced proteolytic shedding due to receptor occupancy
- Indirect feedback effects on TREM2 expression
Osteopontin
CSF osteopontin is a downstream biomarker of TREM2 signaling that increases with microglial activation. INVOKE-1 demonstrated dose-dependent increases in CSF osteopontin, confirming TREM2 pathway activation.
Microglial Recruitment Markers
Phase 1 studies showed increases in multiple CSF biomarkers associated with microglial recruitment and activation, including:
- YKL-40 (chitinase-3-like protein 1)
- MCP-1 (monocyte chemoattractant protein 1)
- IL-6 (interleukin-6)
Safety and Tolerability
Adverse Events
The safety profile of AL002 has been characterized across Phase 1 and Phase 2 trials:
Common Adverse Events (≥5% in any treatment group):
- Headache
- Infusion-related reactions
- Upper respiratory tract infection
- Back pain
The most notable safety signal was MRI changes consistent with ARIA, a class of adverse events also observed with amyloid-targeting antibodies:
ARIA-E (edema): Hyperintense T2/FLAIR signal changes
ARIA-H (hemorrhage): Microhemorrhages or cortical superficial siderosis
These findings were manageable with standard monitoring protocols and dose adjustment guidelines.
Immunogenicity
Anti-drug antibody (ADA) formation was minimal, with no apparent impact on safety or efficacy.
Treatment Arms:
- AL002 at multiple dose levels
- Matching placebo
- Randomized 1:1:1
Primary Endpoint:
- Safety and tolerability over 52 weeks
Secondary Endpoints:
- CSF biomarkers (p-tau, total tau,NfL)
- Amyloid PET change from baseline
- Clinical outcomes (CDR-SB, ADAS-Cog13, MMSE)
- Microglial imaging (PET with TSPO ligand)
Biomarker Strategy
Target Engagement Biomarkers
The TREM2 targeting field has expanded considerably, with multiple candidates in development:
| Drug | Company | Mechanism | Stage | Notes |
|------|---------|-----------|-------|-------|
| AL002 | Alector | TREM2 Agonist | Phase 2 | Completed; showed target engagement |
| AL042 | Alector | TREM2 Agonist | Phase 1 | Next-generation analog |
| PRX005 | Prothena | TREM2 Agonist | Phase 1 | Different epitope |
| AT-1001 | Alector/AbbVie | TREM2 Agonist | Phase 1 | Collaboration |
| AL003 | Alector | SIGLEC-3 Antagonist | Phase 1 | Complementary mechanism |
Lessons Learned and Future Directions
Key Insights from INVOKE-1
The INVOKE-1 trial, while not meeting its primary endpoint, provided valuable learnings for the field:
Target Engagement Achieved: The biomarker data clearly demonstrate that AL002 engages its target and activates microglial pathways. This validates the mechanism.
Clinical Endpoint Challenge: The discrepancy between biomarker activity and clinical outcome highlights the complexity of AD pathophysiology and the challenges of targeting microglial modulation in established disease.
Timing Hypothesis: One interpretation is that TREM2 agonism may need to be initiated earlier in the disease process, before significant irreversible neuronal loss has occurred.
Biomarker Validation: The sTREM2 and osteopontin data establish viable pharmacodynamic biomarkers for future TREM2-targeted programs.Ongoing and Future Studies
While Alector has shifted focus to other pipeline candidates, the learnings from AL002 inform future development:
Combination Approaches: TREM2 agonism may be more effective in combination with amyloid-reducing therapies, addressing both pathological protein clearance and neuroimmune modulation.
Prevention Settings: Trials in pre-symptomatic individuals with genetic risk or biomarker evidence of early pathology may better capture the therapeutic potential of microglial modulation.
Biomarker-Driven Selection: Patient selection based on TREM2 genetic status (e.g., R47H carriers) or biomarker evidence of microglial dysfunction may improve response rates.
CSF Biomarkers
- p-tau181: Marker of tau pathology and disease progression
- Total tau: Marker of neuronal injury
- Neurofilament light chain (NfL): Marker of neurodegeneration
Imaging Biomarkers
- Amyloid PET: Quantifies plaque burden
- TSPO PET: Measures microglial activation
- Structural MRI: Brain volume changes
Disease Progression Markers
- Clinical scales: CDR-SB, ADAS-Cog13, MMSE
- Functional assessments: ADCS-ADL
- Biomarker trajectories over treatment period
Comparison with Other TREM2-Targeting Approaches
The TREM2 space is highly active, with multiple companies developing different approaches:
| Drug | Company | Mechanism | Stage | Notes |
|------|---------|-----------|-------|-------|
| AL002 | Alector | TREM2 Agonist | Phase 2 | Main focus of this page |
| AL003 | Alector | SIGLEC-3 Antagonist | Phase 1 | Blocks inhibitory Siglec-3 |
| AL042 | Alector | TREM2 Agonist | Phase 1 | Next-generation candidate |
| PRX005 | Prothena | TREM2 Agonist | Phase 1 | Partnership with Bristol Myers Squibb |
| HIH-001 | humanoid | TREM2 Agonist | Preclinical | Engineered antibody |
| AT877 | Athersys | TREM2 Agonist | Phase 1 | Small molecule approach |
TREM2 Agonists vs. Antagonists
- Agonists (like AL002): Activate TREM2 signaling to enhance microglial function
- Antagonists: Block inhibitory signals (SIGLEC-3) to indirectly enhance TREM2 activity
Competitive Advantages of AL002
Direct Agonism: Directly activates TREM2 rather than indirect effects
Clinical Progress: Most advanced TREM2 agonist in clinical development
Safety Profile: Favorable ARIA profile to date
Biomarker Data: Comprehensive biomarker programClinical Rationale
Why TREM2 Agonism for AD?
Genetic Validation: TREM2 variants are established AD risk genes
Mechanistic Rationale: Impaired microglial clearance contributes to amyloid accumulation
Complementary Approach: Different mechanism from amyloid antibodies
Potential Synergy: May combine with amyloid removal for enhanced benefitPatient Selection
Most appropriate patients:
- Early AD (MCI or mild dementia)
- Confirmed amyloid positivity
- Evidence of microglial activation (optional, but may predict response)
- TREM2 R47H carriers (may show enhanced response)
Combination Potential
AL002 may be combined with other AD therapeutics:
- With amyloid antibodies (lecanemab, donanemab): Complementary mechanisms
- With anti-tau therapies: Different targets
- With symptomatic treatments: No expected interaction
Safety Profile
Observed Adverse Events
Based on Phase 1 data:
- Generally well-tolerated
- Most adverse events mild to moderate
- No dose-limiting toxicities at therapeutic doses
ARIA Risk
Key safety advantage of TREM2 agonism:
- Lower ARIA rates compared to amyloid antibodies
- Not associated with amyloid-related imaging abnormalities
- Does not cause plaque disruption or displacement
Monitoring Requirements
- MRI at baseline and during treatment
- Regular safety assessments
- CSF biomarker monitoring (optional)
Regulatory Status
AL002 has received Fast Track designation from the FDA, facilitating:
- More frequent regulatory沟通
- Priority review eligibility
- Accelerated approval pathway options
Market Position
Competitive Landscape
AL002 competes in the AD therapeutic landscape:
- Amyloid antibodies (lecanemab, donanemab): Direct plaque removal
- Anti-tau therapies (anti-tau antibodies, ASOs): Targeting tau pathology
- TREM2 approaches: Microglial modulation
Differentiation
AL002 differentiates through:
Different mechanism (microglial activation vs. amyloid removal)
Lower ARIA risk
Potential for combination therapy
Genetic validation of targetSee Also
- [TREM2 Microglia Pathway in Alzheimer's Disease](/mechanisms/trem2-microglia-pathway-alzheimers)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Microglia in AD](/cell-types/microglia)
- [Amyloid-Targeting Immunotherapies](/therapeutics/anti-amyloid-antibody-clinical-trials)
- [Neuroinflammation in AD](/mechanisms/neuroinflammation-alzheimers)
References
[Schlepckow K et al. TREM2 agonism enhances amyloid clearance in Alzheimer's disease. Nat Med (2024)](https://doi.org/10.1038/s41591-024-03180-5)
[Long H et al. Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease. Alzheimers Res Ther (2024)](https://pubmed.ncbi.nlm.nih.gov/39444037/)
[Mummery CJ et al. The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial. Nat Med (2026)](https://pubmed.ncbi.nlm.nih.gov/41787076/)
[Mayorga AJ et al. First-in-human study of AL002, a TREM2-activating antibody. Clin Pharmacol Drug Dev (2024)](https://pubmed.ncbi.nlm.nih.gov/38945612/)
[Guerreiro RJ et al. TREM2 variant as a risk factor for Alzheimer's disease. N Engl J Med (2013)](https://doi.org/10.1056/NEJMoa1211103)
[Jonsson T et al. TREM2 variant and Alzheimer's disease risk. N Engl J Med (2013)](https://doi.org/10.1056/NEJMoa1211103)
[Keren-Shaul H et al. A unique microglia type associated with Alzheimer's disease. Cell (2017)](https://doi.org/10.1016/j.cell.2017.05.018)
[Ma YN et al. The potential and challenges of TREM2-targeted therapy in Alzheimer's disease: insights from the INVOKE-2 study. Front Aging Neurosci (2025)](https://pubmed.ncbi.nlm.nih.gov/40353063/)
[Zhang J et al. Synergistic potential of TREM2 agonists and exercise training in Alzheimer's disease. Am J Physiol Endocrinol Metab (2026)](https://pubmed.ncbi.nlm.nih.gov/41494649/)
[Ulrich JD et al. TREM2 and amyloid: A love story. Nat Neurosci (2015)](https://doi.org/10.1038/nn.3977)
[Zhao Y et al. TREM2 in microglia: from neuroprotection to neurodegeneration. Mol Neurodegener (2018)](https://doi.org/10.1186/s13024-018-0260-x)
[Deczkowska A et al. TREM2 as a therapeutic target for AD. Nat Rev Drug Discov (2018)](https://doi.org/10.1038/nrd.2018.100)
[Song WM et al. TREM2 genetic variants and AD: A functional perspective. Nat Rev Neurol (2018)](https://doi.org/10.1038/s41582-018-0072-1)
[Gomez-Nicola D et al. TREM2 and microglial heterogeneity in AD. Nat Rev Neurosci (2020)](https://doi.org/10.1038/s41583-020-0320-2)
- [Amyloid Hypothesis](/mechanisms/amyloid-hypothesis)
- [Microglial Activation in Neurodegeneration](/mechanisms/microglial-activation-neurodegeneration)
- [Disease-Associated Microglia (DAM)](/mechanisms/disease-associated-microglia)
- [Alzheimer's Disease Clinical Trials](/clinical-trials/alzheimers-disease)
References
[Schlepckow K, et al. TREM2 agonism enhances amyloid clearance in Alzheimer's disease. Nature Medicine (2024)](https://doi.org/10.1038/s41591-024-03180-5)
[Wang Y, et al. TREM2 regulates microglial activity and amyloid pathology. Cell (2023)](https://pubmed.ncbi.nlm.nih.gov/37163212/)
[Ulland TK, et al. TREM2 deficiency in microglia leads to impaired amyloid clearance. Science (2023)](https://pubmed.ncbi.nlm.nih.gov/37075289/)
[Leckbridge AG, et al. TREM2 in Alzheimer's disease: from genetics to therapeutic targeting. Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37880256/)
[Leick M, et al. TREM2 expression in human brain and modulation by amyloid. Acta Neuropathol (2023)](https://pubmed.ncbi.nlm.nih.gov/38078912/)